Business Context and Reporting Period
Company: BioSig Technologies, Inc. (Note: Request metadata listed "Streamex Corp.", but the filing text identifies BioSig Technologies, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: May 1, 2024
Reporting Period: Event date May 1, 2024; Signed May 7, 2024.
Context: The Company entered into a Material Definitive Agreement (Securities Purchase Agreement) with accredited investors to raise capital and convert existing debt.
Key Financial Metrics
Capital Raised: Aggregate consideration of $1,144,164.46.
Cash Proceeds: $634,999.11.
Debt Conversion: $509,165.35 (Principal and accrued interest on a prior Note).
Equity Issued: 783,406 shares of Common Stock at $1.4605 per share.
Warrants Issued: Warrants to purchase up to 391,703 shares at an exercise price of $1.398 per share.
Warrant Terms: Exercisable six months after issuance; expire five and one-half years after issuance.
Prior Debt Instrument: 12% Promissory Note issued March 7, 2024, with a principal of $500,000.
Material Changes
- Debt Reduction: The Company converted the principal balance and accrued interest of a $500,000 Promissory Note (issued March 7, 2024) into equity and warrants, eliminating this specific debt obligation.
- Share Count Increase: Issuance of 783,406 new shares of Common Stock.
- Liquidity Impact: Immediate cash inflow of approximately $635,000.
Guidance, Outlook, and Risks
Management Commentary: The filing summarizes the transaction terms and confirms the sale was made under Section 4(a)(2) and Regulation D exemptions. No specific forward-looking guidance or operational outlook is provided in this text.
Risks and Contingencies: The filing notes that the summaries of the Purchase Agreement and Warrants are not complete and are qualified by reference to the full text of the exhibits. The transaction involves dilution to existing shareholders via new share issuance and warrant grants.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-transaction to assess dilution impact.
- Confirm the total accrued interest amount included in the $509,165.35 conversion figure.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants or restrictions on future financing.
- Check the current market price of BSGM relative to the $1.4605 issuance price and $1.398 warrant exercise price.